Squarepoint Ops LLC purchased a new stake in shares of FibroGen, Inc. (NASDAQ:FGEN – Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 162,914 shares of the biopharmaceutical company’s stock, valued at approximately $145,000.
Several other institutional investors have also recently made changes to their positions in the company. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of FibroGen in the first quarter worth $131,000. Acadian Asset Management LLC grew its stake in shares of FibroGen by 1.4% in the first quarter. Acadian Asset Management LLC now owns 2,503,865 shares of the biopharmaceutical company’s stock worth $5,883,000 after acquiring an additional 34,937 shares in the last quarter. Accel Wealth Management acquired a new position in shares of FibroGen in the first quarter worth $103,000. Point72 DIFC Ltd grew its stake in shares of FibroGen by 734.2% in the second quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 45,990 shares in the last quarter. Finally, XTX Topco Ltd acquired a new position in shares of FibroGen in the second quarter worth $424,000. Hedge funds and other institutional investors own 72.71% of the company’s stock.
FibroGen Trading Up 6.0 %
Shares of FGEN stock opened at $0.36 on Monday. The firm has a fifty day moving average price of $0.39 and a 200 day moving average price of $0.91. The company has a market cap of $35.54 million, a P/E ratio of -0.15 and a beta of 0.70. FibroGen, Inc. has a 12 month low of $0.30 and a 12 month high of $2.93.
Analyst Upgrades and Downgrades
Separately, StockNews.com started coverage on shares of FibroGen in a research note on Sunday. They set a “hold” rating for the company.
Check Out Our Latest Report on FGEN
About FibroGen
FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.
Further Reading
- Five stocks we like better than FibroGen
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Why Fastenal Stock Could Hit New Highs After Strong Q3 Results
- What is a Death Cross in Stocks?
- Why Eli Lilly Stock Is Soaring—and How It Plans to Stay on Top
- Why Invest in High-Yield Dividend Stocks?
- 3 Mid-Cap Stocks Under $20 With Insider Buying and Major Upside
Want to see what other hedge funds are holding FGEN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for FibroGen, Inc. (NASDAQ:FGEN – Free Report).
Receive News & Ratings for FibroGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen and related companies with MarketBeat.com's FREE daily email newsletter.